Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

But the exact mechanisms of how the drug works in the brain in doing things like tamping down food noise, addiction, and now, decreasing Alzheimer's risk, is still under investigation. This isn’t the ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce ...

Researchers at Karolinska Institutet in Stockholm, Sweden, have shown that specific blood biomarkers can predict development of dementia up to 10 years before symptoms appear. But their primary value ...

Not one but two new studies published today have linked GLP-1 drugs like Ozempic to a decreased risk of developing dementia. There is currently no cure for Alzheimer’s, which affects an ...

But bolstered by the early data, Novo Nordisk, the makers of Ozempic and Wegovy, have launched two large-scale phase III trials testing semaglutide for people with early Alzheimer’s disease ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...